At 2 years, 70% of patients on oral icotrokinra for scalp, genital, or hand/foot psoriasis had clear or almost clear skin, with no new safety signals.
|Articles|December 10, 2014
Closing gaps in psoriasis research
Author(s)Lisette Hilton
Listen
0:00 / 0:00
Key Takeaways
- Further research is needed to understand psoriasis prevalence, natural history, and the molecular functions of susceptibility genes to identify new therapeutic targets.
- Environmental factors' roles in psoriasis development and the relationship between cardiometabolic disease and psoriasis require further investigation.
A report published in January 2014 identified several gaps in psoriasis research and recommended research targets to address these gaps.
Advertisement
Dr. Feldman and colleagues reported in January 2014 that gaps remain in psoriasis research. Based on their study, the authors recommend:
- Basic science and clinical research studies to determine the true prevalence and natural history of psoriasis.
- Molecular studies in patients with psoriasis and psoriatic arthritis, looking at the function of psoriasis susceptibility genes and to identify new therapeutic targets.
- Studies examining environmental factors' roles in psoriasis development of psoriasis.
- Investigations centered on the relationship between cardiometabolic disease and psoriasis.
- Studies focused on the potential impact of adjunctive therapies, including psychological interventions.
- And studies to pinpoint disease severity biomarkers and treatment response to improve patient therapy.
Source: Ryan C, Korman NJ, Gelfand JM, Lim HW, Elmets CA, Feldman SR, Gottlieb AB, Koo JY, Lebwohl M, Leonardi CL, Van Voorhees AS, Bhushan R, Menter A. Research gaps in psoriasis: opportunities for future studies. J Am Acad Dermatol. 2014 Jan;70(1):146-67. doi: 10.1016/j.jaad.2013.08.042. Epub 2013 Oct 11. Review.
READ MORE:
Advertisement
Related to this article
Phase 3 LATITUDE Atlas data presented at EADV 2026 showed higher rates of complete and near-complete skin clearance with zasocitinib compared with deucravacitinib.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Advertisement
Advertisement
Trending on Dermatology Times
1
Icotrokinra Sustains Skin Clearance at High-Impact Psoriasis Sites Through 2 Years
2
EADV 2026 Day 3: Long-Term Psoriasis Data and Emerging Therapeutic Targets Take Focus
3
Ritlecitinib Improves Repigmentation in Nonsegmental Vitiligo
4
EADV 2026 Day 2: Long-Term AD Data, GLP-1 Nail Findings, and Emerging Treatments Take Center Stage
5